Evidence map›Paper›PMID 35689296›Full record

ArticleBMC chemistry2022

Efficient synthesis of 1,3-naphtoxazine derivatives using reusable magnetic catalyst (GO-Fe

Soghra Khabnadideh, Aida Solhjoo, Reza Heidari, Leila Amiri Zirtol, Amirhossein Sakhteman, Zahra Rezaei, Elaheh Babaei, Samaneh Rahimi, Leila Emami

Open access · goldAbstract read
In one paragraph

Article in BMC chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Soghra KhabnadidehPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Aida SolhjooDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila Amiri ZirtolPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Amirhossein SakhtemanDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra RezaeiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Elaheh BabaeiDepartment of Chemistry, College of Science, Yazd University, Yazd, Iran.
Samaneh RahimiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. emamil@sums.ac.ir.
Shiraz University of Medical Sciences · IRYazd University · IR

Funding

Shiraz University of Medical Sciences 23994Shiraz University of Medical Sciences 24670
6 · The paper itself

Abstract

A series of 2-aryl/alkyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines (S

Indexed as

1,3-OxazineAnticonvulsantCatalystGO-Fe3O4–Ti(IV)Molecular simulationPTZ

Identifiers

PMID35689296
PMCPMC9188075
OpenAlexW4281665149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.